Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data
Abstract Background Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identif...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-024-00470-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197492157644800 |
|---|---|
| author | Nicole Princic Kristin A. Evans Chintal H. Shah Krystal Sing Salomé Juethner Bob G. Schultz |
| author_facet | Nicole Princic Kristin A. Evans Chintal H. Shah Krystal Sing Salomé Juethner Bob G. Schultz |
| author_sort | Nicole Princic |
| collection | DOAJ |
| description | Abstract Background Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identify populations where frequency modifications may be appropriate. Objective We aimed to describe characteristics of patients who did and did not reduce lanadelumab administration frequency to inform real-world dosing regimens, and characteristics indicative of sustained frequency reduction. Methods A retrospective observational study using healthcare insurance data in the USA from the Merative™ MarketScan® Commercial and Medicare Databases identified patients persistent on lanadelumab for ≥ 18 months. Reduced administration frequency was defined as a ≥ 25% decrease in lanadelumab costs during months 7–12 or 13–18 versus 0–6. Hereditary angioedema attack triggers/symptoms and hereditary angioedema-related healthcare encounters, treatment, and costs were assessed. Results Of 54 identified patients, 25 reduced administration frequency. Two patients returned to initial dosing frequency during months 13–18 after reducing during months 7–12. Patients who reduced administration frequency experienced fewer hereditary angioedema attack triggers/symptoms before lanadelumab initiation (baseline) and during months 0–6 than those who did not; they also had a lower mean number of hereditary angioedema-related inpatient admissions, emergency room visits, and outpatient visits during baseline, had fewer claims for acute treatment (60.0% vs 65.5%) and prior long-term prophylaxis (20.0% vs 27.6%), and had lower mean hereditary angioedema treatment costs at baseline ($139,520 vs $233,815) than those who did not. Conclusions This real-world analysis suggests that patients with less frequent hereditary angioedema-related healthcare encounters, lower disease activity, and lower costs within 6 months before lanadelumab initiation are more likely to achieve reduced dosing frequency. |
| format | Article |
| id | doaj-art-6a2d8539f25f42a6aec2bef8831c5057 |
| institution | OA Journals |
| issn | 2199-1154 2198-9788 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Drugs - Real World Outcomes |
| spelling | doaj-art-6a2d8539f25f42a6aec2bef8831c50572025-08-20T02:13:07ZengAdis, Springer HealthcareDrugs - Real World Outcomes2199-11542198-97882025-01-01121172410.1007/s40801-024-00470-xCharacteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims DataNicole Princic0Kristin A. Evans1Chintal H. Shah2Krystal Sing3Salomé Juethner4Bob G. Schultz5MerativeMerativeUniversity of MarylandTakeda Pharmaceuticals USA, Inc.Takeda Pharmaceuticals USA, Inc.Takeda Pharmaceuticals USA, Inc.Abstract Background Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identify populations where frequency modifications may be appropriate. Objective We aimed to describe characteristics of patients who did and did not reduce lanadelumab administration frequency to inform real-world dosing regimens, and characteristics indicative of sustained frequency reduction. Methods A retrospective observational study using healthcare insurance data in the USA from the Merative™ MarketScan® Commercial and Medicare Databases identified patients persistent on lanadelumab for ≥ 18 months. Reduced administration frequency was defined as a ≥ 25% decrease in lanadelumab costs during months 7–12 or 13–18 versus 0–6. Hereditary angioedema attack triggers/symptoms and hereditary angioedema-related healthcare encounters, treatment, and costs were assessed. Results Of 54 identified patients, 25 reduced administration frequency. Two patients returned to initial dosing frequency during months 13–18 after reducing during months 7–12. Patients who reduced administration frequency experienced fewer hereditary angioedema attack triggers/symptoms before lanadelumab initiation (baseline) and during months 0–6 than those who did not; they also had a lower mean number of hereditary angioedema-related inpatient admissions, emergency room visits, and outpatient visits during baseline, had fewer claims for acute treatment (60.0% vs 65.5%) and prior long-term prophylaxis (20.0% vs 27.6%), and had lower mean hereditary angioedema treatment costs at baseline ($139,520 vs $233,815) than those who did not. Conclusions This real-world analysis suggests that patients with less frequent hereditary angioedema-related healthcare encounters, lower disease activity, and lower costs within 6 months before lanadelumab initiation are more likely to achieve reduced dosing frequency.https://doi.org/10.1007/s40801-024-00470-x |
| spellingShingle | Nicole Princic Kristin A. Evans Chintal H. Shah Krystal Sing Salomé Juethner Bob G. Schultz Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data Drugs - Real World Outcomes |
| title | Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data |
| title_full | Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data |
| title_fullStr | Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data |
| title_full_unstemmed | Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data |
| title_short | Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data |
| title_sort | characteristics of patients with hereditary angioedema who reduced lanadelumab treatment administration frequency a retrospective observational study of us claims data |
| url | https://doi.org/10.1007/s40801-024-00470-x |
| work_keys_str_mv | AT nicoleprincic characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata AT kristinaevans characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata AT chintalhshah characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata AT krystalsing characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata AT salomejuethner characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata AT bobgschultz characteristicsofpatientswithhereditaryangioedemawhoreducedlanadelumabtreatmentadministrationfrequencyaretrospectiveobservationalstudyofusclaimsdata |